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Reduced-intensity conditioning (RIC) regimens have the potential to decrease transplantation-related
morbidity and mortality. However, engraftment failure has been prohibitively high after RIC unrelated um-
bilical cord blood transplantation (UCBT) in chemotherapy-naïve children with nonmalignant diseases
(NMD). Twenty-two children with a median age of 2.8 years, many with severe comorbidities and prior viral
infections, were enrolled in a novel RIC protocol consisting of hydroxyurea, alemtuzumab, ﬂudarabine,
melphalan, and thiotepa followed by single UCBT. Patients underwent transplantation for inherited metabolic
disorders (n ¼ 8), primary immunodeﬁciencies (n ¼ 9), hemoglobinopathies (n ¼ 4) and Diamond Blackfan
anemia (n ¼ 1). Most umbilical cord blood (UCB) units were HLA-mismatched with median infused total
nucleated cell dose of 7.9  107/kg. No serious organ toxicities were attributable to the regimen. The cu-
mulative incidence of neutrophil engraftment was 86.4% (95% conﬁdence interval [CI], 65% to 100%) in a
median of 20 days, with the majority sustaining > 95% donor chimerism at 1 year. Cumulative incidence of
acute graft-versus-host disease (GVHD) grades II to IV and III to IV by day 180 was 27.3% (95% CI, 8.7% to
45.9%) and 13.6% (95 CI, 0% to 27.6%), respectively. Cumulative incidence of extensive chronic GVHD was 9.1%
(95% CI, 0% to 20.8%). The primary causes of death were viral infections (n ¼ 3), acute GVHD (n ¼ 1) and
transfusion reaction (n ¼ 1). One-year overall and event-free survivals were 77.3% (95% CI, 53.7% to 89.8%) and
68.2% (95% CI, 44.6% to 83.4%) with 31 months median follow-up. This is the ﬁrst RIC protocol demonstrating
durable UCB engraftment in children with NMD. Future risk-based modiﬁcations of this regimen could
decrease the incidence of viral infections. (www.clinicaltrials.gov/NCT00744692).
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Allogeneic hematopoietic stem cell transplantation (HSCT)
can cure a variety of nonmalignant diseases (NMD) in chil-
dren, either by direct replacement of abnormal bone marrow
precursors, as in hemoglobinopathies and primary immuno-
deﬁciencies (PID), or indirectly, by providing cellular enzyme
replacement to diseased areas, such as liver and brain, in
inheritedmetabolic disorders (IMD) [1-3]. For patients lacking
matched related donors, unrelated donor umbilical cord
blood transplantation (UCBT) is increasingly being utilized
because of easy availability and less restrictive human leuko-
cyte antigen (HLA) matching requirements. Myeloablativeedgments on page 334.
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13.11.021conditioning (MAC) with UCBT has been used successfully for
2 decades to treat a variety of malignant and NMD [4-7];
however, high transplantation-related mortality (TRM) and
the risks of long-term adverse effects, such as infertility and
secondary malignancies, have remained a barrier for children
with hopefully decades of life expectancy [8-10].
Mixed donor chimerism leads to disease resolution in
patientswith hemoglobinopathies and PID, which can remain
stable over time [11-14]. These observations provide a
rational basis to design reduced-intensity conditioning (RIC)
regimens aimed at decreasing nonhematopoietic toxicity
without compromising the clinical beneﬁts of persistent
donor hematopoiesis. There is a spectrum of RIC regimens,
ranging from minimally intensive/nonmyeloablative to near
ablative with reduced toxicity [13-18]. However, successful
RIC trials were reported mainly after HSCT from living related
or unrelated donors. The use of UCBT after RIC has beenTransplantation.
Table 1
Baseline Patient and Graft Characteristics
UPIN Diagnosis* Age, yr Sex Minority
(Y/N)
Pretransplantation
Comorbidities
Weight on
Day 0, kg
HLA Match 6
Allele
A,B, DRB1
HLA Match 8
Allele Hi res
A, B, C, DRB1
CMV
(Pt)
TNCC
( 107/kg
Reinfused
CD34þ
( 105/kg
Reinfused)
1 Hunter 2.03 M Y Cardiomyopathy, obstructive
sleep apnea
25.3 4/6 6/8 Neg 7.91 3.70
2 Sanﬁlippo B
Syndrome
3.35 M N 15.1 6/6 8/8 Neg 5.18 3.78
3 Sanﬁlippo B
Syndrome
3.32 F N 15.8 5/6 6/8 Neg 4.14 .87
4 Cartilage Hair
Hypoplasia
1.30 M N CMV viremia, transfusion
dependent anemia, chronic
neutropenia
8.2 6/6 7/8 Pos 13.90 4.31
5 MLD 6.76 M N 20.4 5/6 6/8 Neg 4.58 2.43
6 Zap 70 deﬁciency 3.32 F Y Resp: MAI, Pseudomonas,
Parainﬂuenza 1, Candida,
bronchiectasis; Enteroviral
meningitis, hydrocephalus,
VP shunt
11.2 5/6 5/8 Neg 6.60 2.6
7 HLH .45 F N 7.9 5/6 5/8 Neg 15.3 3.67
8 HLH .58 F Y Adenoviremia, adenovirus
in stool and urine
6.20 4/6 4/8 Neg 11.80 2.48
9 b thalassemia major 1.56 M Y 9.5 5/6 6/8 Pos 8.17 5.10
10 CID 1.14 F N ITP, HHV-6 pneumonitis,
Enterovirus encephalitis,
colitis
10.1 5/6 6/8 Neg 7.80 2.73
11 Krabbe 3.09 F Y Blindness 12.2 4/6 5/8 Neg 14.30 4.58
12 Krabbe 3.25 F N Ataxia 19.1 4/6 4/8 Neg 7.36 1.55
13 DBA 2.56 M N Iron overload 15.9 5/6 7/8 Neg 6.22 1.50
14 Hurler 1.71 F Y Obstructive sleep apnea. Stool
adenovirus þ, h/o Parainﬂuenza
3 infection
11.8 4/6 4/8 Neg 10.8 4.86
15 ALD 8.02 M Y 26.9 4/6 3/8 Neg 6.99 3.7
16 bThalassemia major 3.65 M Y 14.2 4/6 5/8 Neg 7.07 1.63
17 B thalassemia major 5.44 F Y Prior myeloablative transplant;
h/o severe hemorrhagic cystitis
18 5/6 6/8 Pos 11 3.5
18 Omenn syndrome .45 M Y 5.26 5/6 6/8 Pos 22 7.72
19 bThalassemia major 2.58 M Y 13.2 6/6 6/8 Neg 5.04 4.58
20 CD40L deﬁciency 3.38 M N 14.1 5/6 7/8 Neg 9.46 3
21 Omenn syndrome .31 M N Erythroderma, FTT, CMV 6 6/6 8/8 Pos 15.8 2.4
22 PNP deﬁciency 4.27 M N FTT, food intolerance, chronic
enteritis, CMV urine,
adenovirus in stool
16.6 5/6 5/8 Pos 5.58 1.3
ALD indicates adrenoleukodystrophy; CID, combined immunodeﬁciency; CMV, cytomegalovirus; DBA, Diamond Blackfan anemia; F, female; FTT, failure
to thrive; HHV-6, human herpes virus 6; Hi res, high resolution; HLH, Hemophagocytic lymphohistiocytosis; h/o, history of; ITP, immune thrombocytopenic
purpura; M, male; MAI, mycobacterium avium; MLD, metachromatic leukodystrophy; Neg, negative; PNP, purine nucleoside phosphorylase; Pos, positive; Pt,
patient; UPIN, patient number; VP, ventriculoperitoneal; Y/N, Yes/no; ZAP 70, zeta chain associated protein kinase 70; TNCC, total nucleated cell count.
* Inherited metabolic disorders (IMD) include Hunter, Hurler, Krabbe, Sanﬁlippo B, metachromatic leukodystrophy (MLD), adrenoleukodystrophy (ALD).
Primary immunodeﬁciency diseases (PID) include Cartilage hair hypoplasia, Zap 70 deﬁciency, HLH, CID, Omenn syndrome, CD40 ligand deﬁciency, PNP
deﬁciency.
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transplantation for malignant conditions, but has been asso-
ciated with high rates of primary graft failure or graft rejec-
tion and autologous reconstitution in chemotherapy-naïve
children, exceeding 50% in patients undergoing single unit
UCBT for hemoglobinopathies [19-22]. In these cases, graft
failure might result from the fact that lower numbers of
infused progenitors may have been unable to outcompete
recovering host hematopoiesis and lymphopoiesis. Therefore,
we developed a novel immunoablative, nevertheless RIC
regimen, designed to establish durable donor cell engraft-
ment, and we report the results of this prospective, single
arm, phase I pilot study in chemotherapy-naïve childrenwith
NMD undergoing single donor UCBT.
METHODS
Patients
From December 2008 to June 2012, 22 children with NMD lacking
matched related donors scheduled to undergo a single UCBT were
enrolled at Duke University, Durham, NC (n ¼ 19) and All Children’s
Hospital, St. Petersburg, FL (n ¼ 3). The study was approved by the
institutional review boards of both institutions. Written assent orinformed consent was obtained from all parents/caretakers or, when
18 years of age, patients, in accordance with the Declaration of Helsinki.
Eligible patients were between 2 months and 21 years of age with a
diagnosis of NMD (PID, IMD, hemoglobinopathies, or other transfusion-
dependent anemias). Patients with IMD exhibiting high performance
status, patients with severe aplastic anemia, and those who had under-
gone HSCT within the previous 6 months were excluded. (www.clinical-
trials.gov NCT00744692).
Donors
Grafts were selected based on HLA Class I (A, B) intermediate-resolution,
and HLA class II (DRB1) allelic level typing. The precryopreservation total
nucleated cell count (TNCC) had to be > 3  107/kg for 5/6 or 6/6 HLA-
matched grafts and > 5  107/kg for 4/6 HLA-matched grafts. Potential
units were screened by international cord blood banking standards and for
normal enzyme activity in IMD patients. Precryopreservation graft charac-
teristics were obtained from the supplying cord blood banks, whereas the
respective hospital laboratories that thawed, washed, and tested the units
provided post-thaw data.
Conditioning Regimen, Graft-versus-Host Disease Prophylaxis,
Transplantation, and Supportive Care
All patients were treated with alemtuzumab 1 mg/kg/dose I.V. on 3
successive days 21 to 19, after a test dose of .2 mg/kg on day 22; hy-
droxyurea 30 mg/kg/day orally from day 22 until day 10; ﬂudarabine
Figure 1. (A) Cumulative incidence of neutrophil engraftment > 500 cells/mm3 with donor cells by day 42. (B) Cumulative incidence of platelet
engraftment > 50,000/mm3 by day 180. (C) Cumulative incidence of acute GVHD, grades II to IV (solid line) and III to IV (dotted line). (D) Cumulative incidence of
chronic GVHD, overall (solid line) and extensive (dotted line).
S.H. Parikh et al. / Biol Blood Marrow Transplant 20 (2014) 326e336328(Flu) 30 mg/m2/day I.V. from days9 to5; melphalan (Mel) 70 mg/m2/day
I.V. on days 4, 3; and thiotepa 200 mg/m2 I.V. on day 2. Frequent baths
(every 4 hours for 24 hours) were prescribed after thiotepa administration.
The thawed and washed UCB unit was infused intravenously on day 0, as
previously described [23,24].
Starting day 3, all patients received graft-versus-host disease (GVHD)
prophylaxis with tacrolimus .03 mg/kg/day I.V. and mycophenolate 15 mg/
kg/dose I.V. every 8 hours. Tacrolimus trough levels were maintained
between 8 and 15 ng/mL. In patients without active GVHD, mycophenolate
was discontinued after 45 days and tacrolimus was tapered 9 months after
transplantation.
Alemtuzumab was administered in the outpatient clinic for most pa-
tients after intensive premedication with acetaminophen, diphenhydra-
mine, ibuprofen, and corticosteroids. All patients were hospitalized in the
Pediatric Blood and Marrow Transplant unit of Duke University Medical
Center or All Children’s Hospital before day 4 and through engraftment
and stabilization post transplantation. Median length of stay for the initial
hospitalization was 47 days (range, 29 to 263). Fungal and antiviral pro-
phylaxis were voriconazole and acyclovir, respectively. Pneumocystis jir-
oveci pneumonia, veno-occlusive disease (VOD) prophylaxis, nutrition,
and transfusion support were as previously described [24]. All patients
received intravenous immunoglobulin (500 mg/kg/dose) weekly until
day þ100, starting day1. Filgrastim (Amgen, Thousand Oaks, CA) was
started at 5 mcg/kg/day on day þ1 and weaned post engraftment. Cyto-
megalovirus (CMV) and adenovirus DNA were monitored weekly post
alemtuzumab. One patient received irradiated, granulocyte colony-
stimulating factor (G-CSF)emobilized, parental granulocyte transfusions
until engraftment for history of Mycobacterium avium, Pseudomonas, and
Candida infections. Four patients subsequently enrolled on the ADV HALT
study (randomized, placebo-controlled, phase 2 Study of preemptive
CMX001 treatment for adenovirus disease prevention); 2 on a multicenter
study of banked third-party virus-speciﬁc T cells to treat CMV, Epstein-
Barr virus (EBV), or adenovirus infections after HSCT [25], and 2 on
expanded access study of human mesenchymal stem cell (Prochymal)infusion for steroid-refractory acute GVHD described in more details un-
der Results.
Post-transplantation Assessments
Engraftment studies were performed by short tandem repeat methods
in whole blood, CD15þ, and CD3þ fractions on days 30, 60, 100, 180, 270,
1 year, and annually thereafter. In parallel, immunophenotyping by 4-color
FACS was performed to quantitate lymphocyte and dendritic cell subsets
[26-28]. Immunoglobulin levels were tested at regular intervals post
transplantation. Organ function and disease-speciﬁc evaluations were per-
formed per institutional practices.
Assessment of Functional T Cell Responses to Microbial Antigens
Multiplex cytokinemeasurements using a cytokine bead array (CBA) and
lymphoproliferative assays as internal controls were set up to test in parallel
for the presence and magnitude of virus-speciﬁc T cell response. Mono-
nuclear cell preps were made and 105 mononuclear cells were seeded per
well of 96well plates in completemedium composed of RPMI 1640,10% PHS,
100 x antibiotic/antimycotic, L-glutamine, Hepes and b-mercaptoethanol,
(Life Technologies Corp, Carlsbad, CA). Viral antigens (Meridian Life Sciences,
Memphis, TN) derived from cytomegalovirus (CMV, R9A104), herpes simplex
virus (HSV, R9A002), and varicella zoster virus (VZV, R02030) were diluted
from frozen stocks and added for a total 200 mL. Negative control wells
received no antigen, whereas positive control wells received 105 ClinExVivo
beads (Life Technologies) as described. Duplicate wells were incubated for
5 days at 37C, and then 75 uL mediumwas removed and frozen for batched
CBA analysis. Secreted cytokines (IFNg, TNFa, IL-10, granulocyte-macro-
phage colony stimulating factor [GM-CSF], IL-2, and IL-4) were quantitated
using the BioPlex (Biorad, Hercules, CA) CBA system. The wells were pulsed
with 25 mL of medium containing 1 mCi of 3H-Thymidine (Perkin Elmer,
Waltham,MA) and incubated for 6 to 8 hours at 37C. Resultswere expressed
numerically as the mean counts per minutes of duplicates as described
[29,30].
Figure 2. Donor Chimerism. (A) Level of whole blood donor chimerism over
time; X-axis ¼ Days after transplantation; Y axis ¼ % of evaluable patients (B)
Level of donor chimerism in whole blood, CD3þ & CD15þ fractions at 1 year
(n ¼ 15).
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Peripheral blood mononuclear cells were prospectively cryopreserved
at deﬁned intervals before and after UCBT. Thymopoiesis was assessed by
ampliﬁcation and quantiﬁcation of delta-deletion T cell receptor excision
circle (TRECs) as previously described [31]. Primers for the TREC sequence
were 50-CCC TTT CAA CCA TGC TGA CAC-30 (forward) and 50-GGG TGC AGG
TGC CTA TGC-30 (reverse), which produced an 80-bp fragment detected
with the probe 50-FAM-TCT GGT TTT TGT AAA GGT GCC CAC TCC TG-BHQ-Table 2
Donor Chimerism
UPIN Day 30 Day 100 Day 180
T L M T L M T
1 >98 95 >98 >98 96 98 >98
2 >98 >98 >98 95 78 90 92
3 10 88 10 63 91 58 Died day
4 0 0 0 Autologous recovery day 30
5 >98 >98 >98 >98 86 >98 >98
6 >98 >98 >98 >98 >98 >98 >98
7 >98 >98 >98 >98 90 >98 >98
8 >98 >98 >98 >98 83 >98 >98
9 >98 >98 >98 >98 >98 >98 >98
10 >98 n/a n/a 94 86 92 >98
11 Engrafted day13, died day 25
12 >98 >98 >98 >98 >98 >98 >98
13 >98 >98 >98 >98 >98 >98 >98
14 Graft failure, died day 24
15 91* 8* 99* Autologous recovery day 41
16 >98 >98 >98 >98 >98 >98 >98
17 >98 >98 >98 >98 >98 >98 >98
18 >98 >98 >98 >98 >98 >98 >98
19 >98 >98 >98 >98 >98 >98 >98
20 87 71 41 87 55 61 88
21 Engrafted day13, died day 27
22 83 >98 68 >98 >98 >98 98
T indicates whole blood; L, CD3þ fraction; M, CD15þ fraction.
Data presented are %.
* ¼ 0% on day 41, thus considered autologous recovery.1-30 . TREC quantiﬁcation was normalized for cell input by parallel quan-
tiﬁcation of the human b-globin gene. The primers for human b-globin
were 50-GAA GAG CCA AGG ACA GGT ACG-30 (forward) and 50-CCT GGG
AGT AGA TTG GCC AA-30 (reverse), which produced an 85-bp fragment
detected by the probe 50-FAM-CTG TCA TCA CTT AGACCT CAC CCT GTG-
BHQ-1-30 .
Statistical Methods
The study was designed as a prospective, single arm, safety and efﬁcacy
pilot study to evaluate the RIC regimen for single UCBT. The primary hy-
pothesis/objective was that the RIC regimen would result in adequate
engraftment deﬁned as the presence of > 25% donor chimerism at 6-
months post-UCBT. Simon’s (optimum) 2-stage design was employed to
test the null hypothesis that the donor engraftment rate is  .30 (Ho:
P  .30) versus the alternative that it is  .65 (Ha: P  .65). Primary graft
failure was deﬁned as the failure to reach ANC > 500/mm3 by day 42 or
absence of donor hematopoiesis  10% in whole blood cells by day 100. The
day 100 and 180 stopping rules for graft failure were not crossed. Cumu-
lative incidence estimates of neutrophil recovery, platelet engraftment,
acute GVHD grades II to IV, acute GVHD grades III to IV, and chronic GVHD
were assessed using standard competing risk analyses with death as a
competing risk [32]. Neutrophil recovery was deﬁned as the ﬁrst day of an
absolute neutrophil count (ANC) > .5  109/L for 3 consecutive days not
secondary to granulocyte infusions; and platelet engraftment as ﬁrst day of
platelet counts > 20  109/L or > 50  109/L for 7 consecutive days without
transfusions as previously described [24]. Acute and chronic GVHD were
graded per established criteria [33,34]. The cumulative incidence of infec-
tion (any, bacterial, viral, or fungal) was estimated from the start of the RIC
regimen using death as a competing risk. The Kaplan-Meier method was
used to describe overall survival (OS) and event-free survival (EFS) [35]. OS
considered a patient death as the event and censored on the last date of
contact, whereas EFS considered death, graft failure, or rejection as the
events. Descriptive statistics of immune reconstitution were provided at 3,
6, 9, 12, and 24 months after UCBT. Analyses were conducted using the SAS
System version 9.3 (Cary, NC).
RESULTS
Patient Characteristics
Patient demographics (N ¼ 22) are shown in Table 1. The
median age was 2.8 years (range, .3 to 8.0) and median
weight was 13.7 kg (range, 5.3 to 26.9) on the day of trans-
plantation. Most patients were males (59%) and Caucasians1 yr 2 yr
L M T L M T L M
98 >98 >98 >98 >98 >98 >98 >98
72 89 92 84 92 88 88 86
170
86 >98 >98 >98 >98 >98 >98 >98
>98 >98 >98 >98 >98 >98 >98 >98
>98 >98 >98 >98 >98 >98 >98 >98
>98 >98 >98 >98 >98 >98 >98 >98
>98 >98 >98 >98 >98 >98 >98 >98
>98 96 96 >98 92 91 >98 92
98 >98 >98 >98 >98 >98 >98 >98
>98 >98 >98 97 >98 >98 >98 >98
>98 >98 >98 >98 >98
>98 >98 >98 >98 >98
>98 >98 >98 >98 >98
>98 >98 >98 96 >98
58 96 87 66 97
>98 97 Died day 258
Figure 3. Immune Reconstitution. Absolute numbers of lymphocyte subsets: CD4þ, CD8þ, CD16,56þ (NK), CD19þ, CD45RAþ/62Lþ/CD4þ (RTE), CD123þ(pDC). Box
plots are shown serially over time for above immune parameters. The diamond in the box represents the mean, while the horizontal line in the box represents the
median. The lower box represents the 25th percentile and the upper box represents the 75th percentile. Upper and lower whiskers represent þ/ 1.5 times the
interquartile range.
Figure 4. Thymopoiesis (TREC and RTE% reconstitution) TREC indicates T cell
receptor excision circles; RTE, recent thymic emigrants (CD45RAþ/CD62Lþ/
CD4þ); median TREC (ﬁlled triangle) and %RTE (ﬁlled circle) are connected
serially over time.
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Asian. Patients were diagnosed with immunodeﬁciency
disorders (n ¼ 9), IMD (n ¼ 8), hemoglobinopathies (n ¼ 4)
and Diamond Blackfan anemia (n ¼ 1). Twenty-one patients
received their ﬁrst HSCT, while 1 patient with thalassemia
major was enrolled 15 months after rejecting a matched
sibling bone marrow transplant (BMT) after MAC regimen.
Graft Characteristics
The median precryopreservation TNCC and CD34þ doses
were 11.1107/kg (range, 5.9 to 31.3) and 4.35105/kg (range,
1.71 to 8.1), respectively. Median infused TNCC and CD34þ
doses were 7.9  107/kg (range, 4.1 to 22) and 3.3  105/kg
(range, .9 to 7.7), respectively. Using conventional HLA
matching criteria to select UCB grafts, donor-recipient
matching was 4/6 in 7 (31.8%), 5/6 in 11 (50%), and 6/6 in 4
(18.2%) patients. Review of HLA typing at allelic level including
HLA-C revealed matches of 3/8 in 1 (4.5%), 4/8 in 3 (13.6%), 5/8
in 5 (22.7%), 6/8 in 8 (36.4%), 7/8 in 3 (13.6%), and 8/8 in 2
(9.1%). Thus, approximately 40% of recipients were mis-
matched for 3 or more loci at the allelic level. Donors were
matched for gender in 12 (55%) and ABO blood type in 10
(45.5%) recipients. Major and/or bidirectional ABO mismatch
were noted in 7 patient/donor pairs (31.8%).
Neutrophil and Platelet Engraftment
The cumulative incidence of neutrophil engraftment with
donor cells by day 42was 86.4% (95% conﬁdence interval [CI],
65% to 100%) (Figure 1A). Nineteen patients engrafted at a
median of 20 days (range, 12 to 28). Three patients experi-
enced graft failure: primary graft failure in 1, who died on
day 24 (unique patient identiﬁcation number [UPIN] 14) with
100% donor cells before engrafting, and autologous recon-
stitution in 2. The latter 2 patients with autologous recon-
stitution (UPIN 15, UPIN 4) successfully underwent secondtransplantations 3.5 and 5 months later; with double UCBT
after myeloablative busulfan (Bu)/cyclophosphamide (Cy)/
antithymocyte globulin (ATG), and with matched unrelated
donor BMT after thiotepa/ATG conditioning, respectively.
Both are alive with donor engraftment. There have been no
secondary graft failures. The cumulative incidence of platelet
engraftment (50,000/uL) by day 180 was 72.7% (95% CI, 47.1%
to 98.3%) occurring in a median of 48 days (range, 33 to 144)
(Figure 1B).
Donor Chimerism
A primary objective of this study was to determine the
proportion of patients engrafted with > 25% donor cells
Table 3
Details of Acute and Chronic GVHD
UPIN Match
Conventional
A,B, DRB1
Match 8
Allele Hi
res A, B,
C, DRB1
AGVHD
Max
Skin
Stage
AGVHD
Max Gut
Stage
AGVHD
Max
Liver
Stage
Acute
GVHD
Grade
Consensus
Chronic
GVHD
cGVHD
Site
AIHA Rituximab MSC GVHD status
at last
follow-up
Immune suppression
status at last
follow-up
1 4/6 6/8 2 0 0 1 No Yes Yes (AIHA, EBV) Resolved Off IS
2 6/6 8/8 1 0 0 1 No Resolved Off IS
3 5/6 6/8 1 0 0 1 No Resolved Died
4 6/6 7/8 NE NE NE NE NE
5 5/6 6/8 0 0 0 0 No Off IS
6 5/6 5/8 3 0 0 2 Extensive Skin Yes Yes (AIHA) Ongoing
7 5/6 5/8 0 0 0 0 Limited Skin Resolved Off IS
8 4/6 4/8 0 0 0 0 Limited Skin Resolved Off IS
9 5/6 6/8 1 0 0 1 Limited Skin Resolved Off IS
10 5/6 6/8 0 1 0 2 Limited Skin Resolved Weaning IS
11 4/6 5/8 0 0 0 0 NE Died
12 4/6 4/8 0 0 0 0 Limited Skin Resolved Off IS
13 5/6 7/8 2 0 0 1 Limited Skin Resolved Off IS
14 4/6 4/8 NE NE NE NE NE Died
15 4/6 3/8 NE NE NE NE NE
16 4/6 5/8 1 3 0 3 No Yes (EBV) Resolved Weaning IS
17 5/6 6/8 3 3 0 3 Extensive Skin, gut Yes Ongoing
18 5/6 6/8 1 0 0 1 Limited Skin Resolved Off IS
19 6/6 6/8 3 0 0 2 No Yes Yes (AIHA) Resolved Weaning IS
20 5/6 7/8 0 0 0 0 Limited Skin Resolved Weaning IS
21 6/6 8/8 0 0 0 0 NE Died
22 5/6 5/8 3 4 0 3 No Yes Died
MSC indicates mesenchymal stem cells; NE, not evaluable; AIHA, autoimmune hemolytic anemia; IS, immune suppression.
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6 months, 16 of whom achieved this endpoint. Speciﬁcally,
whole blood donor chimerism > 90% was demonstrated in
15 of 16 patients at 180 days, 14 of 15 patients at 1 year, and
9 of 10 patients followed at 2 years. Similar levels of donor
cell chimerismwere seen in CD15þ (15 of 16 at 180 days,15 of
15 at 1 year, 9 of 10 at 2 years) and CD3þ fractions (13 of 16 at
180 days, 13 of 15 at 1 year, 9 of 10 at 2 years) (Figure 2 and
Table 2).
Immune Reconstitution
In engrafting patients, the median absolute lymphocyte
and CD4þ Tcell counts at 3, 6, and 12months were 1291 (382Table 4
Treatment and Outcomes of EBV, CMV, Adenovirus Infections
UPIN Infection Treatment Response
1 EBV Rituximab Resolved
2
3 Adenoviremia Cidofovir CTL Resolved
4 CMV viremia Foscarnet, GCV Resolved
5
6
7
8 Adenoviremia CMX001 Resolved
9 CMV viremia Foscarnet, GCV Resolved
10
11 Adenoviremia Cidofovir CMX001 Death
12
13 Adenovirus Cidofovir Resolved
14 Adenovirus Cidofovir CTL Death
15
16 EBV Rituximab Resolved
17 Adenoviremia CMX001 Ongoing treatment due to chronic
18
19
20 Adenoviremia Cidofovir
21 CMV viremia Foscarnet, GCV Death
22 Adenoviremia CMV Cidofovir CMX001 Death
F/U indicates follow-up; EBV, Epstein-Barr virus; CMV, cytomegalovirus; GVHD
cytotoxic T lymphocytes.to 3008) and 154 (0 to 678) (n ¼ 17); 1405 (556 to 4470) and
418 (1 to 1507) (n¼ 16); and 2193 (333 to 5070) and 805 (6 to
2013) (n ¼ 15), respectively (Figure 3). These values are
similar to other pediatric reports using ATG-based rejection
prophylaxis after myeloablative regimens [36-39].
At 180 days, normal, age-adjusted NK, B, and CD4þ
counts were found in 14 of 16 (87.5%), 11 of 16 (68.8%), and
5 of 16 (31.3%) patients respectively. At 1 year, normal, age-
adjusted NK, B, and CD4þ counts were seen in 13 of 15
(86.7%), 12 of 15 (80%), and 12 of 15 (80%) patients,
respectively [40].
Nine of 15 engrafted and surviving patients with a mini-
mum 1-year follow-up are off systemic immunosuppression,F/U (mo) Outcome Day Died Cause of Death
52.9
45.5
Death 170 Hemolytic transfusion reaction
AR
40.4
35.4
34.8
33.6
31.3
30.9
GF Death 25 Disseminated adenoviral infection
26.6
26.4
Death 24 Adenoviremia, Parainﬂuenza 3
AR
16.4
GVHD 15.9
15.5
15.3
14.3
Death 27 CMV pneumonia
Death 258 Acute GVHD, adenoviremia, CMV
, graft-versus-host disease; CTL, trivirus (adenovirus, CMV, EBV)especiﬁc
Figure 5. Kaplan-Meier estimate of (A) overall survival (B) event-free survival.
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available for 14 of 15 patients followed at least 1 year and
were normal in 11 patients, reﬂecting effective T celle
dependent isotype switching by B cells unaffected by possible
intravenous immunoglobulin (IVIG) supplementation, and
IgA levels were low in 3 patients. Two of the patients with
low IgA had received rituximab, and 1 had extensive chronic
GVHD.
Seven of 10 patients followed > 24 months maintain
normal IgG levels without IVIG support.Thymic Output
The appearance of recent thymic emigrants is a
powerful marker of thymopoiesis, critical for acquiring a
broad, naïve T-cell receptor (TCR) repertoire. It was quan-
titated by qPCR for TREC and independently by ﬂow
cytometry monitoring CD45RA and CD62L co-expressing
CD4þ cells. There was a notable paucity of recent thymic
emigrants and TRECþ cells in most patients within the ﬁrst
100 days (Figure 4) followed by a steep rise at day 180,
reﬂecting the resumption of thymopoiesis. The exceptions
were UPIN 22, who died on day þ258 with GVHD com-
plications associated with profound lymphopenia and
recurrence of pretransplantation CMV and adenovirus in-
fections; UPIN 16, who had grade III acute GVHD; and UPIN
17, who had extensive chronic GVHD and had failed a prior
myeloablative transplantation.Antiviral Immunity
Sensitive BioPlex assay monitored the Duke cohort
(n ¼ 19) for virus-speciﬁc cytokines after in vitro challengeTable 5
Causes of Death
UPIN Day Post
Transplantation
Dia
3 170 San
11 25 Kra
14 24 Hu
21 27 Om
syn
22 258 PN
CMV indicates cytomegalovirus; GVHD, graft-versus-host disease; PNP, purine nucwith the herpes family of viruses: CMV, HSV and VZV. The
young age of this study cohort explains the relative low
incidence of pretransplantation exposure: CMV (n ¼ 5), HSV
(n ¼ 1), and VZV (n ¼ 4). There were no VZV-speciﬁc re-
sponses detected, but only 1 seropositive patient was alive/
studied beyond day 100. The 1 patient (UPIN 17) with posi-
tive pretransplantation HSV serology demonstrated speciﬁc
cytokine response ﬁrst at day 180 detectable by simulta-
neous IFNg and GM-CSF secretion (93 pg/mL and 210 pg/mL,
respectively), reﬂecting probable subclinical viral reac-
tivation earlier.
There were 5 patients with pre-UCBT CMV exposure.
Notably, 2 PID patients were viremic already pre-
alemtuzumab: 1 died before day 30 because of CMV pneu-
monia (UPIN 21), and the other had autologous reconstitution
(UPIN 4). Of the other 3 patients, UPIN 22 died of adenovirus
and CMVwith practically no circulating T cells (<10/mL) even
at 6months, whereas UPIN 9 (107 pg/mL) andUPIN 17 (77 pg/
mL) both demonstrated detectable virus-speciﬁc IFNg secre-
tion and proliferative responses by day 100. Neither experi-
enced recurrent CMV viremia. CMV-speciﬁc GM-CSF, IL-13,
and TNFa secretion was also detected but was discordant
between these 2 patients. In sum, anti-CMV and anti-HSV
responses were detected only in seropositive patients and,
when detected, there was no associated disease.Graft-versus-Host Disease
The cumulative incidence of grades II to IV and III to IV
acute GVHD by day 180 was 27.3% (95% CI, 8.7% to 45.9%) and
13.6% (95 CI, 0% to 27.6%), respectively (Figure 1C). The cu-
mulative incidence of any chronic GVHD at 1 year was 40.9%gnosis Cause of Death
ﬁlippo B Hemolytic transfusion reaction
bbe Disseminated adenovirus
rler Adenoviremia, parainﬂuenza 3
enn
drome
CMV pneumonia
P deﬁciency Acute GVHD, adenoviremia, CMV
leoside phosphorylase; UPIN, unique patient identiﬁcation number.
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of extensive chronic GVHD was only 9.1% (95% CI, 0% to
20.8%) (Figure 1D). Of the 10 patients developing chronic
GVHD, 8 had disease limited to skin and 2 had extensive
(skin, n ¼ 1; skin and gut, n ¼ 1) disease. Autoimmune he-
molytic anemia (AIHA) was noted in 3 patients (isolated
AIHA, n ¼ 2; AIHA with chronic GVHD, n ¼ 1; cumulative
incidence, 9.1% [95% CI, 0% to 20.8%]) and responded in all
patients to steroid and rituximab therapy. Of these 12
patients (10 with classic chronic GVHD and 2 additional pa-
tients with isolated AIHA), 5 remain on chronic immuno-
suppression 14 to 35 months post transplantation. Two
patients received mesenchymal stem cell treatment for ste-
roid refractory GVHD. One (UPIN 17) has had a partial
response, whereas the other (UPIN 22) died of acute GVHD,
despite mesenchymal stem cell treatment (Table 3).
Infections
Cumulative incidence of infectious events at 1 year was
high at 90.9% (95% CI, 67.5% to 100%) for any infection, 81.8%
(95% CI, 57.9% to 100%) for viral, 13.6% (95% CI, 0% to 27.7%) for
fungal, and 86.4% (95% CI, 63.1% to 100%) for bacterial in-
fections. CMV, adenovirus, and EBV represented the majority
of viruses encountered.
CMV
Six patients were at risk for CMV disease because of
seropositivity and/or viremia (n ¼ 2). Systemic therapy was
required for 4 of them before transplantation (2 before and 2
after initiation of conditioning), 2 of whom (UPIN 21, UPIN
22), both with PID, developed CMV disease and died after
transplantation.
Adenovirus
Three patients had adenovirus detected before trans-
plantation (2 in stool alone; 1 in stool, urine, and blood), all
of whom developed adenoviremia after transplantation,
including 2 with adenoviral disease. Overall, adenoviremia
developed in 8 of 22 patients (36%) after transplantation,
all of whom received systemic antiadenoviral therapy. Two
patients with inadequate response to cidofovir received
banked third party virus-speciﬁc cytotoxic T lymphocytes.
One of these patients cleared adenoviremia (UPIN 3),
whereas the other patient did not and died on day 24
(UPIN 14). An investigational agent, CMX001, was used to
treat 4 patients. One patient (UPIN 8) had clearance of
adenoviremia and is off CMX001 treatment for > 2 years.
Treatment is ongoing for UPIN 17 because of continued risk
resulting from extensive chronic GVHD and ongoing severe
lymphopenia. Two patients eventually died, 1 (UPIN 11)
with fulminant adenoviral disease on day 25 and another
(UPIN 22) with severe acute GVHD on day 258 with
adenoviral and CMV infections. In all, 3 patients developed
adenoviral disease that was associated with mortality
(Table 4).
EBV
No patient had EBV infection before transplantation. After
transplantation, 2 patients developed EBV infection. EBV
viremia with mesenteric lymphadenopathy was noted in 1
patient (UPIN 1) on day þ88. He responded to rituximab and
is alive and well > 4 years after transplantation. Transient
increase in EBV copy numbers in another patient (UPIN 16)
responded to 2 doses of rituximab, and this patient is alive
>1 year post transplantation.AFB bacteremia
AFB bacteremia was noted in 2 patients: 1 with PID (UPIN
10) on day þ123 and 1 with Krabbe disease (UPIN 12) on
day þ134. Both patients cleared their infections with multi-
drug treatment, and are well > 2 years post transplantation
and off therapy.
Organ Toxicity
This regimen was well tolerated by patients, including
those with signiﬁcant pretransplantation comorbidities
(Table 1). All patients developed some mucositis, which
required parenteral nutrition and analgesia, but VOD, idio-
pathic pneumonitis, pericardial effusion, hemorrhagic
cystitis, or neurologic events attributable to the regimen
were not seen in anyone. One patient who had developed
severe hemorrhagic cystitis during prior BMT needing
approximately 3 months of platelet support, prostaglandin,
and hyperbaric oxygen therapywas enrolled on this study for
a second transplantation and tolerated the RIC regimen well
without recurrence of cystitis. Several other patients had
pretransplantation comorbidities, such as severe bronchiec-
tasis, chronic pulmonary disease, enteroviral meningitis, and
obstructive sleep apnea, and they tolerated the regimenwell
(Table 1).
Survival
Median follow-up of surviving patients is 30.89 months
(range, 14.31 to 52.93). Overall and EFS at 1 year post
transplantation is 77.3% (95% CI, 53.7% to 89.8%) and 68.2%
(95% CI, 44.6% to 83.4%), respectively (Figure 5). Five patients
died (Table 5), of whom 3 died before day þ28 associated
with viral infections. One immunodeﬁcient patient died on
day þ258 from severe acute GVHD with concomitant
adenoviral and CMV disease. Pretransplantation T cell deﬁ-
ciency with adenovirus and CMV detection in stool and
urine, respectively, increased risk for reactivation post
transplantation. One patient, a mixed chimera on day þ100
(total chimerism 63%, 91% lymphoid, 58% myeloid) died on
day þ170 of a hemolytic transfusion reaction after empiri-
cally receiving donor type blood.
DISCUSSION
We report the outcomes of a prospective, pilot study
evaluating a novel RIC regimen consisting of alemtuzumab,
hydroxyurea, ﬂudarabine, melphalan, and thiotepa in a
pediatric cohort of 22 patients with NMD undergoing
single unrelated donor UCBT. The majority of patients (19 of
22) were chemotherapy-naïve and 9 of 22 underwent
transplantation for PID, most of whom arrived at trans-
plantation with pre-existent viral infections (n ¼ 7), reﬂect-
ing their underlying T cell defects. The regimenwas designed
to decrease exposure to alkylating agents, while strength-
ening the immunosuppressive component (ﬂudarabine
and alemtuzumab) with the overall goal of facilitating
donor engraftment while reducing nonhematopoietic organ
toxicity. The cumulative incidence of neutrophil engraftment
was 86%, comparable to myeloablative UCBT, and signiﬁ-
cantly higher than that reported after RIC UCBT in pediatric
NMD (37.5% to 70.6%) [19,22,24,41-45]. Consistent donor
engraftment was noted in patients belonging to diverse
diagnostic groups, including those at a higher risk of
engraftment failure.
Most patients achieved high levels of durable donor
chimerism over the period of observation (median > 24
months). High-level (>90%) whole blood donor chimerism
S.H. Parikh et al. / Biol Blood Marrow Transplant 20 (2014) 326e336334was noted in 14 of 15 patients at 1 year and 9 of 10 patients at
2 years after transplantation. Whole blood chimerism re-
mains > 80% and T cell chimerism remains > 65% in all
engrafted surviving patients (n¼ 15). The durability of donor
engraftment will be monitored long term. We are optimistic
that donor chimerismwill persist given the high (>50%) level
of T cell chimerism in patients thus far. This level of chime-
rism is similar to our previously reported cohort of 159 pa-
tients with IMD undergoing myeloablative single UCBT [24].
All 5 patients with inherited transfusion-dependent anemias
and both patients with hemophagocytic lymphohistiocytosis
(HLH) maintain donor chimerism > 90% at the time of this
report.
Engraftment after UCBT has been a challenge in hemo-
globinopathies even with MAC regimens [19-21,46,47]
because of factors such as compensatory marrow hyperac-
tivity, alloimmunization from frequent transfusions, and the
presence of an immunocompetent, chemotherapy-naïve
host [48]. Retrospective registry analysis of mostly myeloa-
blative UCBT in hemoglobinopathies showed primary graft
failure as the predominant cause of failure, occurring in 27 of
51 patients with 2-year disease-free survival of 45%, despite
an optimal cell dose [20]. With RIC regimens, engraftment is
evenmore challenging. A high graft failure rate with a 2-year
EFS of 50% was recently reported with Bu/Flu/alemtuzumab
[21]. Similarly, in a multicenter study of sickle cell disease
patients undergoing UCBT after a RIC regimen of alemtuzu-
mab/Flu/Mel, 5 of 8 patients had autologous recovery (1-year
EFS of 37.5%) [19]. In these patients, stringent criteria were
used for HLA matching (5/6) and cell dose (median pre-
cryopreservation TNCC 6.4  107/kg; range, 3.1 to 7.6), and,
thus, did not appear to affect the outcome, suggesting that
perhaps the regimen needed to be intensiﬁed to ensure
consistent engraftment. In the current study, the alemtuzu-
mab/Flu/Mel backbone [18,19], which was reported with
increased primary graft failure after single UCBT, was
augmented with thiotepa and hydroxyurea, promoting
engraftment. Thiotepa is a potent immunosuppressive and
myelosuppressive drug and has been successfully used with
melphalan [49-51]. It has promoted engraftment in murine
transplantation models [52,53] as well as in clinical studies
of T celledepleted HSCT and UCBT [54-56]. Hydroxyurea can
induce cycling of the stem cell pool, potentially sensitizing
them to melphalan and thiotepa [57]. Alemtuzumab was
administered distal to UCBT to maximize host immunoa-
blation while reducing its impact on infused donor
lymphocytes.
Of the 2 patients with autologous recovery, cord blood
unit of 1 with cartilage hair hypoplasia lacked in vitro growth
in colony forming unit assay at the time of thaw; the other
with adrenoleukodystrophy received a unit with 3/8 allelic
HLA matching that showed transient full donor engraftment
before being replaced by host cells. Poor graft potency and
immune rejection respectively may have contributed to graft
failure [58,59]. Interestingly, both patients reconstituted host
granulopoiesis within 4 to 6 weeks after transplantation,
consistent with the notion that the preparative regimen is
not fully myeloablative [60]. Both patients underwent suc-
cessful second transplantations and are long-term survivors.
The 2 HLH patients are surviving with > 90% donor
chimerism for> 2 years. TRM is a major barrier for success of
conventional myeloablative regimens in HLH. In a CIBMTR
retrospective HLH study (N ¼ 91), mostly with matched
unrelated donor BMT and Bu/Cy/VP16þ/-ATG, day 100 TRM
was 35% [61]. Alemtuzumab/ﬂudarabine/melphalan hasbeen demonstrated to decrease mortality in children with
HLH receiving BMT with a 3-year survival of 92% compared
with 43% for myeloablative Bu/Cy/ATG [14]. However, several
patients needed donor lymphocyte infusions to sustain
mixed chimerism in the RIC group. Excellent engraftment
and survival was also reported for BMT from Europe [62], but
data with UCBT are limited [63].
This regimenwas well tolerated in terms of organ toxicity,
as there was no cardiac, pulmonary, central nervous system,
renal, or bladder toxicity recorded. Pericardial effusion,
hemorrhagic cystitis, VOD, and multiorgan failure have been
associated with Bu/Cy regimen [64]. Long-term follow-up
will determine the impact of this regimen on late effects.
The major obstacle associated with this regimen is the
high incidence of viral infections. Several factors are likely
contributory. Clearly, patients with underlying T cell immu-
nodeﬁciencies and pretransplantation viral disease were at
extremely high risk for recurrent infections. Nevertheless,
the alemtuzumab dose was relatively high, compared with
some other pediatric studies [14,18,62], and post-UCBT
exposure may have depleted most of the T cells accompa-
nying the grafts, leading to delayed T cell reconstitution until
thymic recovery [65]. Alemtuzumab dose de-escalation
could be explored in the future to allow faster lymphocyte
reconstitution; however, insufﬁcient host immunoablation
could jeopardize engraftment. Patients with pre-existing
viral burdens should either have their transplantations
delayed, when feasible, or use graft sources that would allow
transfer of virus-speciﬁc memory. To further enable the use
of cord blood donor grafts, patients could pre-emptively
receive aggressive antiviral or adoptive immunotherapy
post transplantation.
Taken together, this conditioning regimen is the ﬁrst RIC
regimen, to our knowledge, to result in consistent and du-
rable donor engraftment in children undergoing UCBT for a
variety of diseases, including patients with intact immunity
and high risk for graft failure. It was well tolerated even in
patients with signiﬁcant pretransplantation comorbidities.
Engraftment, survival, acute GVHD, and extensive chronic
GVHD were not inferior to those previously reported after
traditional myeloablative chemotherapy. Immune reconsti-
tution and thymopoiesis were initially slow, but robust after
6 months in most patients. This regimen warrants further
study and optimization for patients with nonmalignant
conditions undergoing UCBT.
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